Lanthanide porphyrinoids as molecular theranostics.
Journal
Chemical Society reviews
ISSN: 1460-4744
Titre abrégé: Chem Soc Rev
Pays: England
ID NLM: 0335405
Informations de publication
Date de publication:
18 Jul 2022
18 Jul 2022
Historique:
pubmed:
7
7
2022
medline:
20
7
2022
entrez:
6
7
2022
Statut:
epublish
Résumé
In recent years, lanthanide (Ln) porphyrinoids have received increasing attention as theranostics. Broadly speaking, the term 'theranostics' refers to agents designed to allow both disease diagnosis and therapeutic intervention. This Review summarises the history and the 'state-of-the-art' development of Ln porphyrinoids as theranostic agents. The emphasis is on the progress made within the past decade. Applications of Ln porphyrinoids in near-infrared (NIR, 650-1700 nm) fluorescence imaging (FL), magnetic resonance imaging (MRI), radiotherapy, and chemotherapy will be discussed. The use of Ln porphyrinoids as photo-activated agents ('phototheranostics') will also be highlighted in the context of three promising strategies for regulation of porphyrinic triplet energy dissipation pathways, namely: regioisomeric effects, metal regulation, and the use of expanded porphyrinoids. The goal of this Review is to showcase some of the ongoing efforts being made to optimise Ln porphyrinoids as theranostics and as phototheranostics, in order to provide a platform for understanding likely future developments in the area, including those associated with structure-based innovations, functional improvements, and emerging biological activation strategies.
Substances chimiques
Lanthanoid Series Elements
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
6177-6209Subventions
Organisme : NCI NIH HHS
ID : R01 CA068682
Pays : United States